Enhertu-Induced Resistant Tumor Models
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
Continue ReadingKnowledge Library
AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma
In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across...
Continue Reading
How Does It Work? | Antibody Drug Conjugates
In this week’s installment of our “How Does It Work?” video series, we explore Antibody Drug Conjugates. Monoclonal antibodies are...
Continue Reading WuXi AppTec Biology Services
WuXi Biology provides a full spectrum of services and solutions to support stand-alone and integrated projects, from target discovery to...
Continue Reading
Evaluation of the efficacy of ADC in vitro and in vivo
Abstract Antibody drug conjugates (ADCs) are promising complexes with therapeutic potential that aimed to the treatment of solid tumor and...
Continue Reading
